SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00299949

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Use of Whole Blood and Cell-rich Coagulation Assays for the Detection of Non-Overt DIC in Sepsis

Sepsis is the 13th most common cause of death in the United States, causing approximately 210,000 deaths per year. Once DIC has developed, irreversible organ injury has already occurred and the mortality rate is 70%. Inhibition of systemic coagulation with activated protein C concentrate has been the only therapy for sepsis introduced in the past several decades which has improved outcomes. Elucidation of the coagulopathic mechanisms early in the development of DIC may give rise to targeted therapies and strategies for early intervention. We hypothesize that an increase in endogenous thrombin potential precedes the development of overt DIC by a clinically significant time period. Our primary objective is to determine if endogenous thrombin potential (ETP) measured at first diagnosis of sepsis prior to the onset of DIC and organ failure is predictive of overt DIC and/or poor outcome. We will compare ETP to standard coagulation assays and the clinical assessment of DIC using the ISTH criteria for overt DIC. A secondary objective of this study is to determine if host coagulation variables predispose to the development of DIC and poor clinical outcome during sepsis.

NCT00299949 Sepsis Disseminated Intravascular Coagulation
MeSH: Sepsis Disseminated Intravascular Coagulation
HPO: Disseminated intravascular coagulation Sepsis


Primary Outcomes

Description: ETP will be used to predict 28 day mortality

Measure: Mortality

Time: 28 days

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 G20210A

Cbc, PT/PTT, Fibrinogen, d-dimer, Protein C activity, Protein S activity, ATIII activity, Factor V Leiden mutation, Prothrombin G20210A mutation analysis will be performed in Memorial Herman Hospital clinical laboratories. --- G20210A ---

The secondary objective will be to compare host coagulation variables, including ETP, roTEG, Pro C, Pro S, ATIII, FVL, and prothrombin G20210A mutation at presentation, with the secondary outcome measures of 28-day mortality and organ dysfunction. --- G20210A ---



HPO Nodes


HPO:
Disseminated intravascular coagulation
Genes 17
CFI CFH NPM1 PRKAR1A TBL1XR1 FIP1L1 SERPIND1 CD46 NLRC4 ZBTB16 STAT5B HELLPAR RARA PML PROS1 NABP1 NUMA1
Sepsis
Genes 68
CYBB RMRP RAG1 RAG2 TGM1 LIG4 SEMA3D NIPAL4 SEMA3C TCF3 MYH11 SAMD9 ATP7A MYLK WAS GALT WIPF1 G6PC3 HLA-B SULT2B1 DCLRE1C MNX1 NRTN ABCA12 CXCR4 PIK3R1 IGHM CYBC1 BTK NFKB2 NCF1 BLNK APC LRRC8A ELANE ACTG2 LMOD1 CYP4F22 AK2 CD79A CD79B ALOXE3 IKZF1 NCF2 NCF4 SERAC1 LIPN CHD7 IGLL1 CTNNB1 PLEC RET ECE1 ADA IL2RG ITGB4 GDNF COG4 ALOX12B MMUT EDN3 EDNRB IL7R FERMT3 TFRC CYBA FOXP3 SDR9C7